Education
About Us
Working with TipRanks
Follow Us
IDNA - ETF AI Analysis
Top Page
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA)
Rating:56Neutral
Price Target:
$26.00
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered solid returns so far this year, indicating strong momentum in its holdings.
Global Diversification
While primarily focused on the U.S., the fund also includes exposure to other regions like Europe and Asia, adding geographic diversity.
Reasonable Expense Ratio
The ETF's expense ratio is relatively low compared to many specialized funds, helping investors keep more of their returns.
Negative Factors
Sector Concentration
The fund is heavily concentrated in the healthcare sector, which could make it vulnerable to industry-specific risks.
Underperforming Holdings
Some top holdings, such as Regeneron and Merck, have shown weak performance this year, which could drag on overall returns.
Small Asset Base
The ETF has relatively low assets under management, which could lead to higher trading costs and less liquidity for investors.
IDNA vs. SPDR S&P 500 ETF (SPY)
AUM124.70M
RegionGlobal
Expense Ratio0.47%
Beta0.94
IssueriShares
Inception DateJun 11, 2019
Dividend Yield1.06%
Asset ClassEquity
Index TrackedNYSE FactSet Global Genomics and Immuno Biopharma Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume41,296
30 Day Avg. Volume28,889
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
36.37Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering43
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IDNA Summary
The iShares Genomics Immunology and Healthcare ETF (IDNA) is an investment fund that focuses on companies leading advancements in genomics, immunology, and healthcare. It includes businesses working on cutting-edge technologies like gene editing, genome sequencing, and personalized medicine. Some of its top holdings are well-known healthcare companies like Regeneron and AstraZeneca. Investors might consider IDNA for its potential long-term growth in the rapidly evolving healthcare and biotechnology sectors. However, it’s important to know that this ETF is heavily focused on healthcare, meaning its performance can be affected by changes in that industry or regulatory challenges.
How much will it cost me?The iShares Genomics Immunology and Healthcare ETF (IDNA) has an expense ratio of 0.47%, which means you’ll pay $4.70 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused fund that requires active management to track innovative companies in genomics and healthcare. The higher cost reflects the specialized nature of the fund.
What would affect this ETF?The IDNA ETF, focused on genomics and healthcare innovation, could benefit from advancements in gene editing, personalized medicine, and increased global healthcare spending, which may drive growth in its top holdings like Revolution Medicines and Regeneron. However, it faces risks from regulatory hurdles, high research costs, and potential market volatility in the healthcare sector, which could impact the performance of companies within the fund. Global economic conditions and changes in government healthcare policies could also influence the ETF's future performance.
IDNA Top 10 Holdings
The IDNA ETF is heavily concentrated in healthcare, with a global mix of companies driving innovation in genomics and immunology. BeiGene is a standout performer, rising on strong revenue growth and strategic market positioning, while Regeneron is lagging due to mixed technical indicators and valuation concerns. AstraZeneca and Roche are steady contributors, supported by robust pipelines and financial performance, though valuation pressures remain. Revolution Medicines has struggled with financial challenges, holding back the fund’s momentum. Overall, the ETF’s focus on cutting-edge biotech offers long-term promise but faces near-term volatility.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Incyte | 5.37% | $6.60M | $20.21B | 27.76% | 81 Outperform | |
| Revolution Medicines | 5.11% | $6.28M | $10.95B | 0.41% | 52 Neutral | |
| ― | 4.67% | $5.74M | ― | ― | ― | |
| Arcellx Inc | 4.64% | $5.71M | $4.89B | -5.88% | 56 Neutral | |
| Regeneron | 4.57% | $5.61M | $66.00B | -21.87% | 79 Outperform | |
| Celcuity | 4.56% | $5.61M | $3.10B | 359.02% | 44 Neutral | |
| BeiGene Ltd | 4.26% | $5.24M | HK$275.52B | 49.20% | 51 Neutral | |
| GlaxoSmithKline | 4.08% | $5.02M | £71.92B | 30.46% | 77 Outperform | |
| AstraZeneca | 4.04% | $4.97M | £194.22B | 31.97% | 76 Outperform | |
| Merck & Company | 3.81% | $4.68M | $209.46B | -16.22% | 79 Outperform |
IDNA Technical Analysis
Positive
―
Price Trends
23.86
Positive
22.69
Positive
21.82
Positive
Market Momentum
0.32
Positive
55.43
Neutral
32.97
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDNA, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 24.86, equal to the 50-day MA of 23.86, and equal to the 200-day MA of 21.82, indicating a bullish trend. The MACD of 0.32 indicates Positive momentum. The RSI at 55.43 is Neutral, neither overbought nor oversold. The STOCH value of 32.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDNA.
IDNA Peer Comparison
Comparison Results
Performance Comparison
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
24.99
-0.08
-0.32%
CRBN
iShares MSCI ACWI Low Carbon Target ETF
―
―
―
IVES
Dan IVES Wedbush AI Revolution ETF
―
―
―
CGW
Invesco S&P Global Water Index ETF
―
―
―
TAN
Invesco Solar ETF
―
―
―
IHAK
iShares Cybersecurity & Tech ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents